|
Montenegro MF, Sáez-Ayala M, Piñero-Madrona A, Cabezas-Herrera J, Rodríguez-López JN. Reactivation of the tumour suppressor RASSF1A in breast cancer by simultaneous targeting of DNA and E2F1 methylation. PLoS One. 2012;7(12):e52231. doi: 10.1371/journal.pone.0052231. Epub 2012 Dec 14. PubMed PMID: 23251702; PubMed Central PMCID: PMC3522638.
AÑO: 2012; IF: 2.74
|
23251702
|
Sáez-Ayala M, Fernández-Pérez MP, Montenegro MF, Sánchez-del-Campo L, Chazarra S, Piñero-Madrona A, Cabezas-Herrera J, Rodríguez-López JN. Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance. Exp Cell Res. 2012 Jun 10;318(10):1146-59. doi: 10.1016/j.yexcr.2012.03.022. Epub 2012 Mar 29. PubMed PMID: 22484375.
AÑO: 2012; IF: 3.383
|
|
Vidal CJ, Montenegro MF, Muñoz-Delgado E, Campoy FJ, Cabezas-Herrera J, Moral-Naranjo MT. The AChE membrane-binding tail PRiMA is down-regulated in muscle and nerve of mice with muscular dystrophy by merosin deficiency. Chem Biol Interact. 2013 Mar 25;203(1):330-4. doi: 10.1016/j.cbi.2012.08.001. PubMed PMID: 22906800.
AÑO: 2013; IF: 2.982
|
|
Sáez-Ayala M, Montenegro MF, Sánchez-Del-Campo L, Fernández-Pérez MP, Chazarra S, Freter R, Middleton M, Piñero-Madrona A, Cabezas-Herrera J, Goding CR, Rodríguez-López JN. Directed phenotype switching as an effective antimelanoma strategy. Cancer Cell. 2013 Jul 8;24(1):105-19. doi: 10.1016/j.ccr.2013.05.009. PubMed PMID: 23792190.
AÑO: 2013; IF: 26.602
|
|
Montenegro MF, Sánchez-del-Campo L, Fernández-Pérez MP, Sáez-Ayala M, Cabezas-Herrera J, Rodríguez-López JN. Targeting the epigenetic machinery of cancer cells. Oncogene. 2015 Jan 8;34(2):135-43. doi: 10.1038/onc.2013.605. Review. PubMed PMID: 24469033.
AÑO: 2015; IF: 7.932
|